Inovio Pharmaceuticals In... (INO)

NASDAQ: INO · Real-Time Price · USD

1.88

-0.06 (-3.09%)

At close: May 01, 2025, 3:59 PM

1.92

2.40%

Pre-market: May 02, 2025, 04:08 AM EDT

-3.09% (1D)

Bid	1.92
Market Cap	68.76M
Revenue (ttm)	217.76K
Net Income (ttm)	-25.25B
EPS (ttm)	-3.95
PE Ratio (ttm)	-0.47
Forward PE	-0.87
Analyst	Buy

Ask	1.93
Volume	729,811
Avg. Volume (20D)	677,773
Open	1.94
Previous Close	1.94
Day's Range	1.81 - 1.94
52-Week Range	1.42 - 13.44
Beta	1.84

About INO

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery o...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Dec 8, 1998

Employees 134

Stock Exchange NASDAQ

Ticker Symbol INO

Website https://www.inovio.com

Full Company Profile

Analyst Forecast

According to 6 analyst ratings, the average rating for INO stock is "Buy." The 12-month stock price forecast is $16.5, which is an increase of 780.00% from the latest price.

Stock Forecasts

Next Earnings Release

Inovio Pharmaceuticals Inc. is scheduled to release its earnings on May 13, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

-1.7%

Shares of industrial stocks are trading lower foll... Unlock content with Pro Subscription

3 months ago

+18.13%

Shares of vaccine makers are trading higher after the first bird flu death was reporting in the US. Additionally, a recent CDC report noted an increase in acute respiratory illness activity.

News

1 week ago · zacks.com

Bet on These 5 Top-Ranked Stocks With Rising P/E

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Carvana, Context Therapeutics Inc, Inovio Pharmaceuticals, ChargePoint and MSA Safety Inc.

3 weeks ago · zacks.com

Inovio (INO) Upgraded to Buy: Here's What You Should Know

Inovio (INO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 month ago · zacks.com

Down -11.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Inovio (INO)

Inovio (INO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates cou...

1 month ago · seekingalpha.com

Inovio Pharmaceuticals, Inc. (INO) Q4 2024 Earnings Call Transcript

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q4 2024 Earnings Conference Call March 18, 2025 4:30 PM ET Company Participants Jennie Willson - IR Jacqui Shea - President & CEO Mike Sumner - Chief Medical...

2 months ago · seekingalpha.com

Inovio Pharmaceuticals Inc (INO) Oppenheimer 35th Annual Healthcare Life Sciences Conference (Transcript)

Inovio Pharmaceuticals Inc (NASDAQ:INO ) Oppenheimer 35th Annual Healthcare Life Sciences Conference February 12, 2025 3:20 PM ET Company Participants Jacqui Shea - CEO and President Conference Call P...

2 months ago · zacks.com

Here's Why Inovio (INO) Could be Great Choice for a Bottom Fisher

Inovio (INO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend...